As the PART study is a feasibility study, embedded within it is a qualitative research investigation (QRI), which will be led by a team at the University of Bristol. This will include interviews with the research team and patients in order to understand the issues surrounding recruitment. It is intended that the results from this will later inform a recruitment strategy for a full trial.
SITU has a new trial!
- 11 September 2014
We are pleased to announce that Professor Freddie Hamdy’s PART trial has been funded by the NIHR HTA. PART is a feasibility, randomised controlled trial which will compare partial ablation (PA) with radical prostatectomy (RP) in men with intermediate risk unilateral prostate cancer.